This is a working overview of 二肽基肽酶-4, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-12. Anything still debated is marked as such rather than presented as settled.
Peptide degradation follows several routes. Hydrolysis cleaves the backbone at susceptible residues, oxidation targets methionine and tryptophan side chains, and aggregation produces higher-molecular-weight species that are difficult to reverse. Light exposure accelerates oxidation, which is why amber glass or opaque secondary packaging is common. Repeated freeze-thaw cycles promote aggregation and are best avoided. Stability-indicating methods detect these changes before they become visible.
Quality control for research material typically involves reversed-phase HPLC for purity and identity, mass spectrometry for molecular weight confirmation, and Karl Fischer titration for residual water content. Peptide content is often reported as the mass of actual peptide rather than total powder mass, since counterions and water contribute to the latter. A certificate of analysis should list the method used for each specification. Limits and acceptance criteria vary by supplier and by intended application.
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
| Property | Value | Notes |
|---|---|---|
| Purity specification (research grade) | Greater than 95 percent by HPLC | Area percent at 220 nm; method dependent |
| Identity confirmation | Mass spectrometry | Observed mass compared with theoretical |
| Residual water | Reported by Karl Fischer titration | Affects peptide content calculation |
| Common synonyms | GLP-1 analog; GLP-1 receptor agonist peptide | Naming varies across catalogs |
| Container material | Low-binding polypropylene | Reduces adsorption at low concentration |
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
=== FA2; 1967 === The new Familia appeared in November 1967 with the same pushrod 987 cc engine as used in the previous generation saloons. It was sold as the "Mazda 1000" in some markets. In July 1968 the rotary-engined version (R100) was introduced, along with a new coupé bodywork which was also available with the 1200 cc piston engine. After an April 1970 facelift (called the "Familia Presto" in the domestic Japanese market), the slightly different OHC "PC" 1-litre engine was also offered. A larger 1169 cc straight-four engined version came along in February 1968, becoming the "Mazda 1200" for export. In this form, the car was first exhibited in Europe at the 1968 Paris Motor Show in the autumn of that year. Power outputs (SAE gross) in Japan of the facelifted, overhead-cam-engined versions were 62 and 75 PS (46 and 55 kW) respectively. The Van (wagon) model was available with either three or five doors, although most export markets only received the five-door version.
== N == David Nachmansohn (1899–1983). German biochemist at Columbia, responsible for elucidating the role of phosphocreatine in energy production in muscles. Member Natl. Acad. Sci. USA Joseph Needham FRS (1900–1995). British biochemist at Cambridge, historian and sinologist, noted for embryology and morphogenesis, and also in Chinese science. Eva J. Neer (1937–2000). American physician and biochemist at Harvard, who researched on G-protein cell biology. Member of the National Academy of Medicine. Joe Neilands (1921–2008). Canadian-born American biochemist and political activist at UC Berkeley, known for studies of microbial iron transport, and as author, with Paul K. Stumpf of Outlines of Enzyme Chemistry. Carl Neuberg (1877–1956). German biochemist at the University of Berlin, a pioneer in the study of metabolism. Michael Neuberger (1953–2013). British biochemist and immunologist at Cambridge University known for delineating the role of DNA deamination in immunity. Hans Neurath (1909–2002). American protein chemist at the University of Washington. He was the Founding editor of Biochemistry, which he edited for 30 years (1961–1991). Member Natl. Acad. Sci. USA. Eric Newsholme (1935–2011). British biochemist at the University of Oxford who specialised in human metabolism. Hermann Niemeyer (1918–1991). Chilean biochemist. National Prize of Science (Chile). Member of the Academy of Science of Chile. Marshall Warren Nirenberg (1927–2010).
=== Thirds, fourths === The term "minute" usually means 1⁄60 of an hour, coming from "a minute division of an hour". The term "second" comes from "the second minute division of an hour", as it is 1⁄60 of a minute, or 1⁄60 of 1⁄60 of an hour. While usually sub-second units are represented with SI prefixes on the second (e.g. milliseconds), this system can be extrapolated further, such that a "third" would mean 1⁄60 of a second (16.7 milliseconds), and a "fourth" would mean 1⁄60 of a third (278 microseconds), etc. These units are occasionally used in astronomy to denote angles.
Sources: en.wikipedia.org
The University of Pittsburgh Medical Center (UPMC) is an American integrated global nonprofit health enterprise that has 100,000 employees, 40 hospitals with more than 8,000 licensed beds, 800 clinical locations including outpatient sites and doctors' offices, a 3.8 million-member health insurance division, as well as commercial and international ventures. It is closely affiliated with its academic partner, the University of Pittsburgh. It is considered a leading American health care provider, as its flagship facilities have ranked in U.S. News & World Report "Honor Roll" of the approximately 15 to 20 best hospitals in the U.S. for over 15 years. As of 2016, its flagship hospital UPMC Presbyterian was ranked 12th nationally among the best hospitals (and first in Pennsylvania) by U.S. News & World Report and ranked in 15 of 16 specialty areas when including UPMC Magee-Womens Hospital. This does not include UPMC Children's Hospital of Pittsburgh which ranked in the top 10 of pediatric centers in a separate US News ranking.
As expected, deramciclane reaches greatest peak plasma concentrations with intravenous administration, followed by intraperitoneal, then oral administration with the lowest peak plasma concentration. Studies assessing the elimination half-life of deramciclane point to a range of 20–32 hours for T1/2. The elimination half-life appears to increase with dosage. There is some evidence for accumulation of deramciclane, though it is a topic of debate. Deramciclane undergoes side chain modification and oxidation at multiple positions on the molecule. The side chain reaction forms phenylborneol and N-desmethylderamciclane which is the active metabolite of deramciclane. Oxidation of the molecule results in many hydroxy-, carboxy-, and N-oxide derivatives. Clinical studies investigating the effects of food or lack thereof on deramciclane adsorption show that there is a statistically significant, but not clinically relevant, increase in bioavailability of deramciclane when administered with food because the point of critical instability of deramciclane is relatively low at a pH of 2. The presence of food does not affect deramciclane's elimination half-life (T1/2) or mean residence time (MRT).
Bicalutamide is metabolized in the liver by hydroxylation and glucuronidation. The metabolites of bicalutamide are not known to be active. The medication has a very long biological half-life of 6 days with a single dose and 7 to 10 days with repeated administration. Bicalutamide and its metabolites are eliminated in urine, feces, and bile, mainly in the form of conjugates. The pharmacokinetics of bicalutamide are not influenced by food, age, body weight, renal impairment, or mild-to-moderate hepatic impairment, but ethnicity may influence its pharmacokinetics in some cases.
Sources: en.wikipedia.org
Sealed, protected from light, and refrigerated at two to eight degrees Celsius for most research material. Desiccated storage limits moisture uptake. Allow the vial to reach room temperature before opening to prevent condensation.
Each cycle exposes the peptide to ice-liquid interfaces where unfolding and aggregation can occur. Aggregates may not redissolve and can alter measured activity. Aliquoting before the first freeze reduces the number of cycles any single portion experiences.
It usually reports purity by HPLC, identity by mass spectrometry, peptide content, appearance, and residual moisture or counterion content. The analytical method behind each value should be stated. Acceptance criteria are set by the supplier or the buyer's specification.
差别集中在三处：第 8 位残基被非天然氨基酸取代，第 34 位换成精氨酸，第 26 位增加一条脂肪酸侧链。前两处改动降低酶解速率，侧链则通过白蛋白结合延长循环时间。综合结果是半衰期从约两分钟延长到约一周。